Previous 10 | Next 10 |
WALTHAM, Mass., April 26, 2022 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (Nasdaq: ETTX), a late-stage clinical biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced that top-line data from the company’s pi...
WALTHAM, Mass., April 18, 2022 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (Nasdaq: ETTX), a late-stage clinical biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced that the company will deliver multiple data pre...
Phase 3 ATTACK registrational trial for sulbactam-durlobactam (SUL-DUR) achieved all primary and secondary endpoints, NDA submission planned for mid-2022 Zoliflodacin Phase 3 trial progressing; enrollment completion now anticipated in 2023 Entasis’ pathogen-directed platf...
WALTHAM, Mass., Feb. 02, 2022 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (Nasdaq: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced that its Board of Directors received a preliminary, n...
Gainers: Palisade Bio (NASDAQ:PALI) +23%. Pharming Group (NASDAQ:PHAR) +14%. Entasis Therapeutics (NASDAQ:ETTX) +13%. Epizyme (NASDAQ:EPZM) +11%. IceCure Medical (NASDAQ:ICCM) +10%. Losers: LogicBio Therapeutics (NASDAQ:LOGC) -50%. Pardes Bios...
Entasis Therapeutics (NASDAQ:ETTX) is trading ~15% higher in the pre-market after announcing that its existing investor, Innoviva submitted a non-binding proposal to buy the shares it currently does not own for $1.80 per common share in an all-cash transaction. The purchase price in...
MDJM (NASDAQ:MDJH) +64%. The OLB Group OLB +25% reports $1.35B in transaction value post CBD Merchants acquisition. Advanced Micro Devices AMD +13% on Q4 results. Xilinx (NASDAQ:XLNX) +12%. Capri Holdings CPRI +12% on Q3 results. IceCure Medical (NASDAQ:ICCM) +11%. Arrival...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Good morning, investor! We’re beginning another busy day of trading with a look at the biggest pre-market stock movers for Wednesday! Source: ventdusud / Shutterstock.com News moving stocks this morning inclu...
WALTHAM, Mass., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a late-stage clinical biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced that the Company will be participating in the H.C. W...
Entasis Therapeutics is a clinical stage biopharmaceutical company developing targeted antibacterial products against multidrug resistant pathogens. The Company was spun-out in 2015 as a wholly owned subsidiary of AstraZeneca. The Company recently announced positive topline result...
News, Short Squeeze, Breakout and More Instantly...
Entasis Therapeutics Holdings Inc. Company Name:
ETTX Stock Symbol:
NASDAQ Market:
Entasis Therapeutics Holdings Inc. Website:
WALTHAM, Mass., Oct. 12, 2022 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. , a late-stage clinical biopharmaceutical company focused on the discovery and development of novel antibacterial products, and wholly owned subsidiary of Innoviva, Inc. (Nasdaq: INVA), today announced ...
Innoviva, Inc. (Nasdaq: INVA) (“Innoviva”) today announced that its tender offer to purchase any and all issued and outstanding shares of common stock of Entasis Therapeutics Holdings Inc. (Nasdaq: ETTX) (“Entasis”) at a price of $2.20 per share, net to the s...
WALTHAM, Mass., June 09, 2022 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (Nasdaq: ETTX), a late-stage clinical biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced multiple presentations at the American Society...